# Julie R. Brahmer

Source: https://onco.cc/people/julie-brahmer/  
OnCo record `julie-brahmer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer.

## Summary

Julie R. Brahmer is Director of Thoracic Oncology and Co-Director of the Upper Aerodigestive Department at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a thoracic oncologist known for leading CheckMate 017, the first trial to show immunotherapy beats chemotherapy in lung cancer, alongside early PD-L1 antibody work. Her selected paper reports nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. She is also a long-term follow-up author of the first-line pembrolizumab trials and works on mesothelioma.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Thoracic Oncology; Co-Director, Upper Aerodigestive Department, Bloomberg~Kimmel Institute
- Specialisms: Lung cancer immunotherapy; PD-1/PD-L1; Mesothelioma

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Julie_Brahmer
- Hopkins profile: https://www.hopkinsmedicine.org/profiles/details/julie-brahmer
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Brahmer%20JR%5BAuthor%5D

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/)
- key papers: [CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy](https://onco.cc/key-papers/paper-checkmate-017-nejm-2015/), [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/), [Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer](https://onco.cc/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/)

---
JSON: https://onco.cc/api/v1/entities/julie-brahmer.json